Clinical trial
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With…
NCT00278941 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00278941 |
|---|---|
| Title | Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder |
| Official title | A Multi-Centre, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder |
| Acronym | AMETHYST |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate Sustained Release |
| Enrollment | 3,000 |
| Start date | Dec 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Jan 19, 2006 |
| Last update posted | Mar 25, 2009 |
| Countries | Bulgaria, Canada, Puerto Rico, Romania, Russia, Slovakia, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: